Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.

Trial Details

NCT ID
NCT07278362
Phase
PHASE4
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Testosterone cypionate
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Males aged ≥ 18 years old
  • Newly diagnosed with low-risk prostate cancer initially confirmed by fusion guided prostate biopsy (transrectal or trans perineal) by multiparametr…
  • Males diagnosed with low-risk prostate cancer on active surveillance
  • Two confirmatory testosterone levels \<350 ng/dL (taken before 10am), with at least 24 hours and no more than 90 days between the two tests

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →